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What do we need for staging of lung cancer patients in the new millennium? Some likeit pure and simple, with only clinical symptoms paving the way.1 Others would like
us to include positron emission tomographic staging in any patient.2 Based on restricted
resources, there is in general a growing trend to include only investigations that are “cost
effective” into the staging of lung cancer patients. But where do we really stand in the new
millennium?
1. We have learned that systemic treatment for lung cancer has become more
effective and is worth delivering to an increasing number of patients spanning the
gamut from the advanced to the more early, operable stages.3
2. The last 10 years have seen enormous progress in the treatment of single or
oligotrophic metastases to the brain with the development of stereotactic radio-
therapy and gamma-knife surgery. Although surgery for single brain metastases
may be adequate in selective cases, high rates of local control can also be reached
with these new techniques.4 The article by Shi et al. in this Journal gives new
arguments and stimulus for this issue.5
The article reports the data set of a retrospective analysis of a large, single-center
experience over several years with imaging-based staging of lung cancer patients with
either brain computed tomographic scan, magnetic resonance imaging (MRI), or both. The
authors have especially looked at the distribution of symptomatic and asymptomatic
patients within the subset of patients in whom brain metastases were found at initial
staging. Moreover, they have looked at the distribution of different patient characteristics
from histopathology and gender to tumor and node factors among those with diagnosed
brain metastases. Although there may be several theoretical arguments for possible biases
within such a retrospective analysis—especially when not all patients have had brain
MRI—there are important messages to be learned from their results.
One-third of the patients showing brain metastases at initial imaging were clinically
or neurologically asymptomatic. Clinical characteristics could not help to identify these
patient groups. The number of patients with T1 and N1 characteristics with proven brain
metastases was astonishingly high, especially in patients with adenocarcinoma and
large-cell carcinoma.
Where do we go from here? First, we still cannot adequately predict the risk of
metastases by any clinical patient characteristic. Therefore, in asymptomatic patients, we
do not have the means to select patients within staging adequately enough for brain
imaging investigations.
Second, the number of asymptomatic brain metastases that would be missed should
no brain staging be performed on asymptomatic patients would be high: 27 patients with
single brain metastases and 34 patients with multiple brain metastases would be missed if
staging were to be based only on neurologic symptoms. This represented 61 of 809 (7.5%)
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patients included in the report by Shi and colleagues in this
issue of the Journal of Thoracic Oncology.
Some years ago, we would have had only the possibil-
ity of treating selected single brain metastases by surgery and
postoperative radiotherapy with a locally curative intent. It is
understood that only for a few of these patients would this
have meant cure—only in those in whom small primary
tumors could have been removed by thoracotomy. However,
this is changing, as today we can offer stereotactic radiother-
apy for patients with small single brain metastases or a small
number of (thus oligotrophic) brain metastases. High local
control rates are achieved with this new measure, and some
patients may even be cured while primary tumors are ade-
quately treated.4 Even more, the palliative implications of this
should not be underestimated: symptomatic brain metastases
still mean debilitating disease, loss of personal freedom, and
an extensive handicap for a large percentage of those patients
that may render them to be supported by costly professional
health care workers or nurses.
Should we perform randomized trials with year-long
follow-up and amalgamation into meta-analysis 10 years later
to develop evidence-based guidelines for our staging in the
new millennium? Definitely not. However, a careful prospec-
tive and continuing analysis of staging policies within tho-
racic oncology centers or better multicenter multimodality
treatment groups seems more than advisable and probably
necessary. These prospective data sets should be critically
reanalyzed from time to time, openly reported, and thus made
transparent.
Implications for the individual patients should be care-
fully and critically estimated. Joining of databases would be
a perfect goal for the future and would help to identify both
quality-of-life issues and economic implications on a wider
scale.
The economic argument—if given alone—is far from
being honest: cisplatin, probably the most important cancer
drug in solid tumor oncology, was extremely expensive when
it entered clinical routine in the 1980s.6 Today, it is the
cheapest of all and costs only a few cents—hardly dollars.
Even the potent antiemetics used to support it have become
considerably cheaper. Only the extensive increase in its
clinical use over the years has made this economic develop-
ment possible. If it had been confined and restricted to
individual cases in selected patients, where it clearly had been
shown to be cost effective, we would still have to pay
thousands of dollars for it today, and only a few pharmaceu-
tical companies would have an interest in distributing it. The
same will eventually hold true for brain MRI: the more
routinely we perform it, the cheaper it will eventually be-
come, and even computerized “robotic” reporting of results
seems now in sight. Nevertheless, a transparent and exter-
nally evaluated mechanism for pricing of these imaging
modalities is a prerequisite for such policies to lessen eco-
nomic conflicts of interest for the performing doctors, hospi-
tal administrators, health workers, and others.
What is left to us? We as lung cancer doctors have the
responsibility of developing the prospective data sets to shed
light into this darkness and to make our work scientifically
controllable and analyzable. Brain metastasis remains one of
the most important issues in the management of lung cancer
patients worldwide. Frankly, this article is only the begin-
ning, and a lot of work remains to be done.
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